IceCure Medical (TASE:ICCM) - Aktienkurs, Nachrichten und Analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ICCM Aktienübersicht

A commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. Mehr Details

ICCM grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	2/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	5/6
Dividenden	0/6

Belohnungen

93.7% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes jährliches Umsatzwachstum 47.49%

Risikoanalyse

Hat weniger als 1 Jahr Cash Runway

Hat keine nennenswerte Marktkapitalisierung (₪194M)

Die Aktionäre wurden im vergangenen Jahr verwässert

Hat keine nennenswerten Einnahmen ($3M)

+ 1 mehr Risiko

IceCure Medical Ltd Wettbewerber

BrainsWay

TASE:BWAY

₪695.1m

Pulsenmore

TASE:PULS

₪147.6m

SofWave Medical

TASE:SOFW

₪621.4m

Bio-View

TASE:BIOV

₪32.3m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für IceCure Medical
Historische Aktienkurse
Aktueller Aktienkurs	₪4.25
52-Wochen-Hoch	₪14.97
52-Wochen-Tief	₪3.34
Beta	1.6
11 Monat Veränderung	3.71%
3 Monate Veränderung	-11.91%
1 Jahr Veränderung	-27.13%
33 Jahre Veränderung	-16.00%
5 Jahre Veränderung	-33.86%
Veränderung seit IPO	-99.33%

Aktuelle Nachrichten und Updates

Will IceCure Medical (TLV:ICCM) Spend Its Cash Wisely?

Jul 13

Recent updates

Aktionärsrenditen

	ICCM	IL Medical Equipment	IL Markt
7D	-3.6%	1.8%	1.6%
1Y	-27.1%	3.4%	25.8%

Rendite im Vergleich zur Industrie: ICCM übertraf die Branche IL Medical Equipment , die im vergangenen Jahr eine Rendite von 3.4 erzielte.

Rendite vs. Markt: ICCM hinter dem Markt IL zurück, der im vergangenen Jahr eine Rendite von 25.8 erzielte.

Preisvolatilität

Is ICCM's price volatile compared to industry and market?
ICCM volatility
ICCM Average Weekly Movement	5.0%
Medical Equipment Industry Average Movement	5.8%
Market Average Movement	4.1%
10% most volatile stocks in IL Market	7.3%
10% least volatile stocks in IL Market	2.9%

Stabiler Aktienkurs: ICCM hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: ICCMDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 43% auf 5% zurückgegangen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2006	69	Eyal Shamir	www.icecure-medical.com

IceCure Medical Ltd's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von IceCure Medical im Vergleich zum Marktanteil des Unternehmens?
ICCM grundlegende Statistiken
Marktanteil	₪194.08m
Gewinn(TTM)	-₪59.62m
Umsatz(TTM)	₪11.15m

17.4x

Kurs-Umsatz-Verhältnis

-3.3x

Kurs-Gewinn-Verhältnis

Ist ICCM zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ICCM Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$3.05m
Kosten der Einnahmen	US$1.72m
Bruttogewinn	US$1.33m
Sonstige Ausgaben	US$17.63m
Umsatz	-US$16.30m

Zuletzt gemeldete Gewinne

Mar 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.36
Bruttomarge	43.67%
Nettogewinnspanne	-534.74%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich ICCM auf lange Sicht entwickelt?

Historische Performance und Vergleiche

This company listing is no longer active

ICCM Aktienübersicht

Belohnungen

Risikoanalyse

IceCure Medical Ltd Wettbewerber

TASE:BWAY

₪695.1m

TASE:PULS

₪147.6m

TASE:SOFW

₪621.4m

TASE:BIOV

₪32.3m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Will IceCure Medical (TLV:ICCM) Spend Its Cash Wisely?

New major risk - Financial position

New major risk - Revenue and earnings growth

IceCure Medical Ltd to Report Q1, 2023 Results on May 22, 2023

Insufficient new directors

Full year 2022 earnings released: US$0.46 loss per share (vs US$0.35 loss in FY 2021)

Recent updates

Will IceCure Medical (TLV:ICCM) Spend Its Cash Wisely?

New major risk - Financial position

New major risk - Revenue and earnings growth

IceCure Medical Ltd to Report Q1, 2023 Results on May 22, 2023

Insufficient new directors

Full year 2022 earnings released: US$0.46 loss per share (vs US$0.35 loss in FY 2021)

Here's Why We're Watching IceCure Medical's (TLV:ICCM) Cash Burn Situation

IceCure Medical Ltd Receives Notice of Allowance from the U.S. Patent and Trademark Office for Its Patent Application Titled Cryogen Pump

IceCure Medical Ltd Receives Notice of Patent Allowance in Japan for A Novel Cryogenic Pump for Its Next-Generation Cryoablation Systems

IceCure Medical Ltd Announces Interim Results from the ICESECRET Study for the Treatment of Patients with Small Renal Masses

IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.091 loss in 3Q 2021)

IceCure Medical Ltd to Report Nine Months, 2022 Results on Dec 05, 2022

IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures

IceCure Medical Ltd. Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery

Are Investors Undervaluing IceCure Medical Ltd (TLV:ICCM) By 29%?

IceCure Medical Ltd Submits Regulatory Filing in Vietnam for Approval of Prosense®

Second quarter 2022 earnings released

IceCure Medical Ltd to Report Q2, 2022 Results on Aug 15, 2022

IceCure Medical Ltd Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors

IceCure Medical Ltd to Report Q1, 2022 Results on May 18, 2022

Full year 2021 earnings released: US$0.35 loss per share (vs US$0.27 loss in FY 2020)

Is IceCure Medical Ltd (TLV:ICCM) Potentially Undervalued?

IceCure Medical Ltd, Annual General Meeting, Mar 03, 2022

Icecure Medical Ltd Medical Receives Notice of Intention to Grant A European Patent Covering Its Cryogenic Pump

Is IceCure Medical (TLV:ICCM) In A Good Position To Deliver On Growth Plans?

IceCure Medical's Interim Results of the ICE3 Clinical Trial for Early-Stage Breast Cancer Cryoablation featured at the 2021 Annual Meeting of the Radiological Society of North America

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Icecure Medical Announces First Peer Reviewed Publication for the 3-Year Interim Analysis of the Ice3 Trial on Cryoablation of Low-Risk, Early-Stage Breast Cancer

Icecure Medical Ordinary Shares Deleted from Other OTC

IceCure Medical Ltd. Announces Positive Interim Results from ICE3 Clinical Trial for Breast Cancer Treatment by Freezing with the ProSense® Cryoablation System Presented at the 2021 ASBrS Meeting

Full year 2020 earnings released: ₪0.11 loss per share (vs ₪0.15 loss in FY 2019)

IceCure Signs Exclusive Distribution Agreement with Rise General Trading, LCC, Expanding Market Reach Across the Middle East

New 90-day high: ₪1.48

New 90-day high: ₪0.70

IceCure Medical Ltd Inks Expanded Distribution Agreement with Terumo Corporation for Thailand

New 90-day high: ₪0.72

IceCure Medical Ltd Expands Strategic Collaboration with Terumo Corporation, New Commercial Distribution Agreement Potentially Valued at over $7.0 Million

IceCure Medical Ltd has completed a Follow-on Equity Offering in the amount of ILS 20.7 million.

New 90-day low - ₪0.52

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

IceCure Medical Ltd's Grundlagenzusammenfassung

17.4x

-3.3x

Erträge &amp; Einnahmen

Erträge & Einnahmen